Phase 1/2Not yet recruiting
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
- Sponsor
- Dr David Hasan, M.D. (Academic or other)
- Enrollment
- 82 planned
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Tirofiban; Placebo
- Ages
- adults, older adults
- Registry
- NCT07493577
Full record on ClinicalTrials.gov
From the registry
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Primary outcomes
- Tirofiban dosage-limiting toxicity (DLT)
History
Study completion expected
Primary completion expected
Expected to start
Last registry update
Registered